Showing 6111-6120 of 8473 results for "".
- Sun Pharma, Cassiopea Move Ahead with Winlevi Agreementhttps://practicaldermatology.com/news/sun-pharma-cassiopea-move-ahead-with-winlevi-agreement/2460899/Sun Pharma and Cassiopea SpA announced the expiration of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the exclusive License and Supply Agreements signed by both companies for Winlevi (clascoterone cream 1%).
- First Patient Dosed in Kinnate's Phase 1 trial of KIN-2787 in Patients with BRAF Mutation-Positive Solid Tumorshttps://practicaldermatology.com/news/first-patient-dosed-in-kinnates-phase-1-trial-of-kin-2787-in-patients-with-braf-mutation-positive-solid-tumors/2460894/The first patient has commenced treatment in Kinnate Biopharma Inc.’s Phase 1 KN-8701 trial of its lead RAF product candidate, KIN-2787, a pan-RAF inhibitor being developed for the treatment of patients with melanoma, lung cancer, and other solid tumors. While three kina
- FDA Approves Amendment to Avita's Vitiligo Trial Designhttps://practicaldermatology.com/news/fda-approves-amendment-to-avitas-vitiligo-trial-design/2460893/Avita Medical, Inc. will move forward with an amended pivotal clinical trial evaluating the safety and effectiveness of the RECELL® System for the repigmentation of stable vitiligo lesions to a streamlined single-arm trial design, now that the FDA has approved the trial modification. The
- New AKN Classification System May Improve Treatmenthttps://practicaldermatology.com/news/new-akn-classification-system-may-improve-treatment/2460852/A new classification system aims to improve the way that Acne Keloidalis Nuchae or AKN is treated. AKN can begin as tiny bumps on the back of the head, typically following a close haircut. However, due to a patient's genetic predisposition, these lesions become unremitt
- Golden State Dermatology Adds Concord Practicehttps://practicaldermatology.com/news/golden-state-dermatology-adds-concord-practice/2460850/Curtis A. Raskin, MD, PhD, FAAD and his team are now part of Golden State Dermatology. The clinic in Downtown Concord adds to the eight new locations Golden State added in 2020, after adding eight in 2019. Dr. Raskin received his medical degree and PhD in molecular biology from State Un
- Chicago Area Shade Structures to be Dedicatedhttps://practicaldermatology.com/news/chicago-area-shade-structures-to-be-dedicated/2460844/The Deerfield Park District on Monday dedicates Shade Structures installed at Jewett Park Preschool Playground. Len Kasper, the radio play-by-play announcer for the Chicago White Sox, leads the dedication and will share his personal messa
- Water's Edge Partners with Goodman Dermatologyhttps://practicaldermatology.com/news/waters-edge-partners-with-goodman-dermatology/2460837/Water’s Edge Dermatology has partnered with Goodman Dermatology, P.C., a general and cosmetic dermatology practice in Atlanta. Water’s Edge Dermatology recently merged with Riverchase Dermatology (collectively, “WED/RCD”) and is a leading provider of compreh
- Dermatologist Named as AMA President-Electhttps://practicaldermatology.com/news/dermatologist-named-as-ama-president-elect/2460835/Jack Resneck Jr, MD, a dermatologist from the San Francisco Bay Area, is the new president-elect of the American Medical Association (AMA). Following a year-long term as president-elect, Dr. Resneck will assume the office of AMA president in June 2022. “It is truly an honor t
- CellFX from Pulse Biosciences Cleared in Canadahttps://practicaldermatology.com/news/cellfx-from-pulse-biosciences-cleared-in-canada/2460833/The CellFX® System from Pulse Biosciences is now approved via a Medical Device License from Health Canada for use in dermatological procedures requiring ablation and resurfacing of the skin for the reduction, removal, and/or clearance of cellular-based benign lesions. Puls
- Can Blocking the Function of the CCR6 Chemokine Help Treat Psoriasis and Psoriatic Arthritis?https://practicaldermatology.com/news/can-blocking-the-function-of-the-ccr6-chemokine-help-treat-psoriasis-and-psoriatic-arthritis/2460825/A novel chemical blocker targeting chemokine proteins may significantly reduce skin and joint inflammation in psoriasis and psoriatic arthritis, according to a study in mice. Chemokines are small molecules with a critical role in the body’s response to inflammation and infection.